Despite being hailed as a breakthrough in HIV prevention, the long-acting injectable drug lenacapavir has yet to reach Latin America, leaving a high-risk region without access to one of the most promising tools in the fight against the virus. While global health leaders have praised the drug's efficacy, its rollout has been uneven, and the gap is becoming increasingly hard to ignore.

A Game-Changer Stuck in Limbo

Lenacapavir, a twice-yearly injectable PrEP (pre-exposure prophylaxis) option, has generated enormous excitement in the medical community. Clinical trials have shown it to be highly effective at preventing HIV infection, offering an alternative to daily pills that many find difficult to adhere to. The drug's long-acting nature could be particularly transformative for vulnerable populations, including young women and men who have sex with men, where adherence to daily prevention is often a challenge.

However, the reality on the ground in Latin America is starkly different. The drug remains unavailable in most countries across the region, despite the fact that HIV incidence rates in parts of Latin America are among the highest in the world. Health advocates argue that the delay is not just a regulatory or logistical issue but a matter of equity and public health urgency.

Why the Delay? A Complex Web of Barriers

The reasons behind lenacapavir's absence in Latin America are multifaceted. Regulatory approval processes in the region can be slow, and even when authorized, high costs often put the drug out of reach for public health systems. Pharmaceutical companies have been criticized for prioritizing wealthier markets where they can command higher prices, leaving lower- and middle-income countries waiting longer for access.

Additionally, infrastructure challenges play a significant role. The drug requires cold-chain storage and trained healthcare workers to administer injections, which may not be available in all settings. Advocacy groups have called on governments and manufacturers to speed up negotiations, issue voluntary licenses, and invest in local production capacity to make the drug available and affordable.

What's at Stake for the Region?

Latin America has made significant strides in HIV treatment and prevention over the past two decades, but new infections continue to occur at alarming rates, particularly among key populations. The arrival of lenacapavir could dramatically shift the prevention landscape, but each month of delay means more people become infected who could have been protected.

Public health experts stress that the drug is not a silver bullet, but it is a powerful addition to the prevention toolkit. Without it, the region risks falling further behind in its goal to end the AIDS epidemic by 2030, a target set by the United Nations.

Global Calls for Equitable Access

The situation in Latin America mirrors a broader global challenge: ensuring that revolutionary medical advances reach everyone, not just those in wealthy nations. International organizations, including UNAIDS and the World Health Organization, have repeatedly emphasized the need for equitable access to HIV prevention tools. They have urged pharmaceutical companies to adopt tiered pricing, technology transfer, and generic licensing agreements to expand availability.

Some progress has been made in other regions, with generic versions of lenacapavir being produced in countries like India, but Latin America has yet to benefit from these efforts. Activists are now pressuring regional health ministries to take proactive steps, including joint procurement mechanisms and regional regulatory harmonization, to fast-track approval and distribution.

What Can Be Done?

To bridge the gap, a coordinated approach is needed. Governments must prioritize HIV prevention and allocate sufficient budgets to procure new drugs. Manufacturers should work with local agencies to register the drug quickly and at fair prices. Civil society organizations can play a key role in advocating for access and educating communities about the benefits of long-acting PrEP.

The lessons from the COVID-19 pandemic have shown that global health equity is achievable when there is political will and public pressure. The same energy must now be directed toward HIV prevention.

Key Takeaways

  • Lenacapavir is a highly effective, long-acting injectable HIV prevention drug, but it remains unavailable in most of Latin America.
  • Regulatory delays, high costs, and infrastructure gaps are the primary barriers to access in the region.
  • Global health organizations and activists are calling for equitable access, including generic licensing and tiered pricing.
  • Immediate action is needed to prevent new HIV infections and meet regional public health goals.

As the world watches, the question remains whether Latin America will catch up or continue to be left behind in the fight against HIV. The answer will depend on the collective will of governments, industry, and civil society to put health equity first.